Christine A. Garcia, MD, MPH, FASCO (@christinemphmd) ranks #31 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 7 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CROWN, CHRYSALIS-2. CMS Open Payments lists $27,461 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 2 trials discussed by name
- Lung Cancer: US #31 · 7 physicians engaged
- CMS Open Payments lists $27,461 in 2025 general payments.
This Month
What Christine A. Garcia, MD, MPH, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Christine A. Garcia, MD, MPH, FASCO
Physicians who reposted Christine A. Garcia, MD, MPH, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #31 | — | 7 | 7 | Full ranking |
Trials Christine A. Garcia, MD, MPH, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CROWN | 2 | #14 of 36 | May 30, 2026 |
| CHRYSALIS-2 | 1 | #11 of 14 | May 29, 2026 |
Christine A. Garcia, MD, MPH, FASCO on CROWN
Still thinking about the landmark CROWN 7-year lorlatinib update. Beyond the stats, this represents real, meaningful time for our patients & families living life while managing scans, visits, & AEs. CROWN is setting a phenomenal new benchmark for all TKIs to strive for! #ASCO26 https://t.co/jvVJ8n4FHS
🫁 Amazing CROWN 7-year update at #ASCO26 Dr. @TonyMok9: In 1L advanced ALK+ NSCLC, median PFS with lorlatinib is STILL not reached at 7 yrs! 📊 7-yr PFS 55% vs 3% (crizotinib), HR 0.19 🧠 No new intracranial progression after 30 mo Longest PFS ever reported in advanced NSCLC! https://t.co/80b6SI2b7a
Christine A. Garcia, MD, MPH, FASCO on CHRYSALIS-2
CHRYSALIS-2 OS update | #ASCO26 Cohort C 1L amivantamab + lazertinib in ATYPICAL EGFR-mutated NSCLC (n=49): 📊 Median OS 41.0 mo (~3.5 yrs) • 55% alive at 3y, 46% at 4y • 20% still on 1L tx at cutoff ~2x the historical ~19.4 mo with afatinib. #LCSM #LungCancer https://t.co/377qVW73tq
Christine A. Garcia, MD, MPH, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Striking new #lungcancer screening data: You need to screen fewer high-risk never-smokers to catch a cancer than heavy smokers. #ASCO26 #lcsm Number Needed to Screen (NNS): -TALENT (Never-smokers) =150 -NELSON (Smokers) = 222 -NLST (Smokers) = 320 https://t.co/ViuDw0u5IS
Fantastic event w/ @OncBrothers summarizing the major updates from #ASCO26! 🩺🔥 Brilliant insights from an all-star panel on #lungcancer featuring @StephenVLiu, @NarjustFlorezMD, & @RManochakian. Caught up w/ @RManochakian to discuss exciting progress in small cell lung cancer! https://t.co/xYCnaDnsBS
#ASCO26 is almost here! 🩺 Save the date to digest the biggest #LungCancer updates with this great panel on June 10 at the @OncLiveSOSS State of the Science Summit. 📍 Register: https://t.co/EwPAOHHWNU @ipreeshagul @ElaineShumMD @mjeng21 @NickRohsMD @HemOncFellows #lcsm #MedEd https://t.co/b1ZiIEriJe
Love this Lopes’ List! Great day 1 #ASCO26 #lcsm summary @GlopesMd! https://t.co/d9cOCskXBO
#lcsm: Which trials besides the TWO lung cancer plenaries are you most excited for at #ASCO2026? Weigh in on the Roon Round: https://t.co/GbBb9mswSX @DrAshish_Saxena @Jonathanwlee23 @lungoncdoc @ipreeshagul @sands_jacob @RManochakian https://t.co/uwtyeT8qFc
Industry Payments
CMS Open Payments · 2025 general payments
$27,461 across 20 payments